IDH2 and central nervous system cancer: In light of the association of IDH-mutant gliomas with mutations in tumor-suppressor genes including TP53, ATRX, CIC, NOTCH1, and FUBP1 [41], it stands to reason that IDH1R132H expression becomes permissible and therefore detectable in these gliomas of various grades [36].